Form 4: Dermata Therapeutics Senior VP Acquires 20,000 Stock Options

Dermata Therapeutics' Senior VP, Christopher J. Nardo, acquired 20,000 stock options at an exercise price of $1.38 on January 13, 2025.

Summary

• Christopher J. Nardo, Senior VP and CDO of Dermata Therapeutics, acquired 20,000 stock options on January 13, 2025.
• The exercise price for these options is $1.38 per share.
• The options vest as to 25% after 12 months from the grant date, and the remaining 75% vest in 36 equal monthly installments starting after the 12-month anniversary.
• The options expire on January 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a senior executive can be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard transaction for executive compensation in publicly traded companies, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of 25% after one year and the remaining 75% over three years is a typical vesting structure for stock options.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the executive's performance leads to an increase in the company's stock price.

Key Dates

Keywords

stock options, insider trading, executive compensation, Dermata Therapeutics, DRMA, Christopher J. Nardo